Market Research Logo

Pancreatitis - Pipeline Review, H2 2015

Pancreatitis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Pancreatitis - Pipeline Review, H2 2015’, provides an overview of the Pancreatitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pancreatitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pancreatitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pancreatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pancreatitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pancreatitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pancreatitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Pancreatitis Overview
Therapeutics Development
Pipeline Products for Pancreatitis - Overview
Pipeline Products for Pancreatitis - Comparative Analysis
Pancreatitis - Therapeutics under Development by Companies
Pancreatitis - Therapeutics under Investigation by Universities/Institutes
Pancreatitis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Pancreatitis - Products under Development by Companies
Pancreatitis - Products under Investigation by Universities/Institutes
Pancreatitis - Companies Involved in Therapeutics Development
Atox Bio Inc.
CalciMedica, Inc.
D-Pharm Ltd.
Dynavax Technologies Corporation
Generon (Shanghai) Corporation Ltd.
GlaxoSmithKline Plc
Pharming Group N.V.
Pancreatitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AB-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEM-28-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEM-2814 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CM-128 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DPB-99 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DV-1179 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F-652 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2795039 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-6288B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-2pal18S - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PZ-235 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SBP-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SBP-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-20201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pancreatitis - Recent Pipeline Updates
Pancreatitis - Dormant Projects
Pancreatitis - Discontinued Products
Pancreatitis - Product Development Milestones
Featured News & Press Releases
Jul 30, 2015: D-Pharm receives final report for Phase 2 clinical study of DP-b99 in acute high-risk pancreatitis patients
Jun 12, 2014: D-Pharm's DP-b99 Prevents Abnormal Neuronal Plasticity and Pathological Brain Reorganization
Jan 14, 2014: D-Pharm Announces Recruitment of the First Patient Into Its Phase 2 Clinical Trial With DP-b99 in Acute High-Risk Pancreatitis
Nov 21, 2013: D-Pharm starts Phase 2 Clinical Study with DP-b99 in Acute High-Risk Pancreatitis Patients
Oct 14, 2013: D-Pharm Schedules Investigators Meeting to Discuss Protocol of Phase 2 Clinical Study of DP-b99 for Acute High-Risk Pancreatitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pancreatitis, H2 2015
Number of Products under Development for Pancreatitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Pancreatitis - Pipeline by Atox Bio Inc., H2 2015
Pancreatitis - Pipeline by CalciMedica, Inc., H2 2015
Pancreatitis - Pipeline by D-Pharm Ltd., H2 2015
Pancreatitis - Pipeline by Dynavax Technologies Corporation, H2 2015
Pancreatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2015
Pancreatitis - Pipeline by GlaxoSmithKline Plc, H2 2015
Pancreatitis - Pipeline by Pharming Group N.V., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Pancreatitis Therapeutics - Recent Pipeline Updates, H2 2015
Pancreatitis - Dormant Projects, H2 2015
Pancreatitis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Pancreatitis, H2 2015
Number of Products under Development for Pancreatitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report